Dizal reports positive Phase 3 lung cancer drug results

Dizal has announced encouraging topline results from its Phase 3 WU-KONG28 study for ZEGFROVY®, an oral, once-daily treatment for non-small cell lung cancer. The study evaluated ZEGFROVY® against a standard chemotherapy doublet, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival. These positive findings represent a significant advancement in the treatment of first-line non-small cell lung cancer, offering a potentially more effective and convenient therapeutic option for patients.